

Olli Kampman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/905040/publications.pdf>

Version: 2024-02-01

95
papers

1,864
citations

236925

25
h-index

302126

39
g-index

97
all docs

97
docs citations

97
times ranked

2803
citing authors

#	ARTICLE	IF	CITATIONS
1	Sleep in Psychotic Disorders: Results From Nationwide SUPER Finland Study. Schizophrenia Bulletin Open, 2022, 3, .	1.7	2
2	Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder. Pharmacogenomics Journal, 2022, 22, 166-172.	2.0	6
3	The role of alcohol use and adiposity in serum levels of IL-1RA in depressed patients. BMC Psychiatry, 2022, 22, 158.	2.6	1
4	Adverse childhood experiences and social and occupational functioning in first-episode psychosis " A one year follow - up. Psychiatry Research, 2022, 311, 114502.	3.3	0
5	Differences in psychosocial functioning between psychotic disorders in the Finnish SUPER study. Schizophrenia Research, 2022, 244, 10-17.	2.0	1
6	Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder. Brain Sciences, 2021, 11, 688.	2.3	3
7	Electroconvulsive therapy increases temporarily plasma vascular endothelial growth factor in patients with major depressive disorder. Brain and Behavior, 2021, 11, e02001.	2.2	6
8	Reaction Time and Visual Memory in Connection to Alcohol Use in Persons with Bipolar Disorder. Brain Sciences, 2021, 11, 1154.	2.3	1
9	Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine. Psychiatry Research, 2021, 306, 114227.	3.3	2
10	Impact of Comorbid Alcohol Use Disorder on Health-Related Quality of Life Among Patients With Depressive Symptoms. Frontiers in Psychiatry, 2021, 12, 688136.	2.6	5
11	Reaction Time and Visual Memory in Connection to Hazardous Drinking Polygenic Scores in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder. Brain Sciences, 2021, 11, 1422.	2.3	0
12	Association of Income With the Incidence Rates of First Psychiatric Hospital Admissions in Finland, 1996-2014. JAMA Psychiatry, 2020, 77, 274.	11.0	19
13	Importance of congruence between communicating and executing implementation programmes: a qualitative study of focus group interviews. Implementation Science Communications, 2020, 1, 94.	2.2	0
14	Clozapine-Related Diarrhea and Colitis. Journal of Clinical Psychopharmacology, 2020, 40, 293-296.	1.4	7
15	Implementing physical exercise and music interventions for patients suffering from dementia on an acute psychogeriatric inpatient ward. Nordic Journal of Psychiatry, 2019, 73, 401-408.	1.3	7
16	M79 THE INTERPLAY BETWEEN SCHIZOPHRENIA AND INTELLIGENCE POLYGENIC RISK SCORES CONTRIBUTES TO COMMUNITY FUNCTIONING IN PEOPLE WITH PSYCHOTIC DISORDER. European Neuropsychopharmacology, 2019, 29, S209.	0.7	0
17	Manifesto for an international digital mental health network. Digital Psychiatry, 2019, 2, 14-24.	2.1	14
18	Assessment of alcohol consumption in depression follow-up using self-reports and blood measures including inflammatory biomarkers. Alcohol and Alcoholism, 2019, 54, 243-250.	1.6	5

#	ARTICLE	IF	CITATIONS
19	What is important for the sustained implementation of evidence-based brief psychotherapy interventions in psychiatric care? A quantitative evaluation of a real-world programme. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 185-194.	1.3	4
20	Status of inflammation and alcohol use in a 6-month follow-up study of patients with major depressive disorder. <i>Alcohol</i> , 2019, 81, 21-26.	1.7	7
21	The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. <i>Journal of Neural Transmission</i> , 2019, 126, 35-45.	2.8	27
22	Low tumor necrosis factor- α levels predict symptom reduction during electroconvulsive therapy in major depressive disorder. <i>Brain and Behavior</i> , 2018, 8, e00933.	2.2	10
23	O5.5. SLEEP IN MAJOR PSYCHIATRIC DISORDERS: RESULTS FROM NATIONWIDE SUPER FINLAND STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S88-S88.	4.3	0
24	The effects of adiposity and alcohol use disorder on adipokines and biomarkers of inflammation in depressed patients. <i>Psychiatry Research</i> , 2018, 264, 31-38.	3.3	10
25	Genetic Polymorphisms Associated With Constipation and Anticholinergic Symptoms in Patients Receiving Clozapine. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 193-199.	1.4	5
26	BDNF and NRG1 polymorphisms and temperament in selective serotonin reuptake inhibitor-treated patients with major depression. <i>Acta Neuropsychiatrica</i> , 2018, 30, 168-174.	2.1	3
27	Temperament clusters associate with anxiety disorder comorbidity in depression. <i>Journal of Affective Disorders</i> , 2018, 236, 252-258.	4.1	4
28	Temperament and character profiles are associated with depression outcome in psychiatric secondary care patients with harmful drinking. <i>Comprehensive Psychiatry</i> , 2018, 84, 26-31.	3.1	4
29	The association of alcohol use and quality of life in depressed and non-depressed individuals: a cross-sectional general population study. <i>Quality of Life Research</i> , 2018, 27, 1217-1226.	3.1	8
30	Outcome of neuropsychiatric symptoms and daily functioning of patients with dementia treated on an acute psychogeriatric ward. <i>Nordic Journal of Psychiatry</i> , 2018, 72, 521-525.	1.3	4
31	Effect of electroconvulsive therapy on brain-derived neurotrophic factor levels in patients with major depressive disorder. <i>Brain and Behavior</i> , 2018, 8, e01101.	2.2	15
32	Pessimism, diet, and the ability to improve dietary habits: a three-year follow-up study among middle-aged and older Finnish men and women. <i>Nutrition Journal</i> , 2018, 17, 92.	3.4	16
33	Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 65.	2.6	38
34	Behavioral activation versus treatment as usual in naturalistic sample of psychiatric patients with depressive symptoms: a benchmark controlled trial. <i>BMC Psychiatry</i> , 2018, 18, 238.	2.6	9
35	Histaminergic gene polymorphisms associated with sedation in clozapine-treated patients. <i>European Neuropsychopharmacology</i> , 2017, 27, 442-449.	0.7	11
36	Anxiety Disorders and Temperament—An Update Review. <i>Current Psychiatry Reports</i> , 2017, 19, 27.	4.5	32

#	ARTICLE	IF	CITATIONS
37	Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 89-95.	1.3	12
38	<i>INSIG2</i> polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine. <i>Pharmacogenomics</i> , 2016, 17, 1987-1997.	1.3	7
39	Pessimism and risk of death from coronary heart disease among middle-aged and older Finns: an eleven-year follow-up study. <i>BMC Public Health</i> , 2016, 16, 1124.	2.9	26
40	Outcome of patients with dual diagnosis in secondary psychiatric care. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 470-476.	1.3	8
41	Temperament and character profiles associated with depression and treatment response in patients with or without comorbid substance abuse. <i>Psychiatry Research</i> , 2016, 245, 250-258.	3.3	10
42	Psychiatric hospital admission and long-term care in patients with very-late-onset schizophrenia-like psychosis. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 355-360.	2.7	6
43	Acute Psychogeriatric Inpatient Treatment Improves Neuropsychiatric Symptoms but Impairs the Level of Functioning in Patients with Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 40, 290-296.	1.5	10
44	Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET) gene polymorphisms: Susceptibility and treatment response of electroconvulsive therapy in treatment resistant depression. <i>Neuroscience Letters</i> , 2015, 590, 116-120.	2.1	17
45	Early assessment of implementing evidence-based brief therapy interventions among secondary service psychiatric therapists. <i>Evaluation and Program Planning</i> , 2015, 52, 182-188.	1.6	5
46	SERT and NET polymorphisms, temperament and antidepressant response. <i>Nordic Journal of Psychiatry</i> , 2015, 69, 531-538.	1.3	16
47	Factors associated with subjective side-effects during clozapine treatment. <i>Nordic Journal of Psychiatry</i> , 2015, 69, 161-166.	1.3	10
48	Smoking and weight among patients using clozapine. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 620-625.	1.3	4
49	Polymorphism in alpha 2A adrenergic receptor gene is associated with sialorrhea in schizophrenia patients on clozapine treatment. <i>Human Psychopharmacology</i> , 2014, 29, 336-341.	1.5	16
50	Meta-Analysis of Anxiety Disorders and Temperament. <i>Neuropsychobiology</i> , 2014, 69, 175-186.	1.9	40
51	Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. <i>Psychiatry Research</i> , 2014, 218, 277-283.	3.3	56
52	CYP1A2 polymorphism <i>rs2470890</i> (rs2470890) is associated with increased side effects to clozapine. <i>BMC Psychiatry</i> , 2014, 14, 50.	2.6	14
53	A Cluster Model of Temperament as an Indicator of Antidepressant Response and Symptom Severity in Major Depression. <i>Psychiatry Investigation</i> , 2014, 11, 18.	1.6	6
54	Association between vitamin b12 levels and melancholic depressive symptoms: a Finnish population-based study. <i>BMC Psychiatry</i> , 2013, 13, 145.	2.6	32

#	ARTICLE	IF	CITATIONS
55	TPH1A218C polymorphism and temperament in major depression. <i>BMC Psychiatry</i> , 2013, 13, 118.	2.6	14
56	Efficacy of electroconvulsive therapy: is it in the <i>BDNF</i> gene?. <i>Pharmacogenomics</i> , 2013, 14, 1365-1368.	1.3	2
57	Effects of S-Ketamine as an Anesthetic Adjuvant to Propofol on Treatment Response to Electroconvulsive Therapy in Treatment-Resistant Depression. <i>Journal of ECT</i> , 2013, 29, 158-161.	0.6	68
58	No support for a role for BDNF gene polymorphisms rs11030101 and rs61888800 in major depressive disorder or antidepressant response in patients of Finnish origin. <i>Psychiatric Genetics</i> , 2013, 23, 33-35.	1.1	14
59	BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression. <i>Psychiatric Genetics</i> , 2013, 23, 134-136.	1.1	18
60	One-Year Follow-Up After Discontinuing Maintenance Electroconvulsive Therapy. <i>Journal of ECT</i> , 2012, 28, 225-228.	0.6	31
61	Relationships between depressive symptoms and self-reported unintentional injuries: the cross-sectional population-based FIN-D2D survey. <i>BMC Public Health</i> , 2012, 12, 516.	2.9	9
62	Prevalence of metabolic syndrome in subjects with melancholic and non-melancholic depressive symptoms. A Finnish population-based study. <i>Journal of Affective Disorders</i> , 2012, 136, 543-549.	4.1	40
63	Association between folate intake and melancholic depressive symptoms. A Finnish population-based study. <i>Journal of Affective Disorders</i> , 2012, 138, 473-478.	4.1	12
64	Lifetime leisure-time physical activity and the risk of depressive symptoms at the ages of 65-74years: The FIN-D2D survey. <i>Preventive Medicine</i> , 2012, 54, 313-315.	3.4	16
65	P2RX7 polymorphisms Gln460Arg and His155Tyr are not associated with major depressive disorder or remission after SSRI or ECT. <i>Neuroscience Letters</i> , 2011, 493, 127-130.	2.1	37
66	Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. <i>Neuroscience Letters</i> , 2011, 501, 20-24.	2.1	26
67	Can onset and recovery in depression be predicted by temperament? A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2011, 135, 20-27.	4.1	117
68	Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 95-102.	3.2	29
69	Temperament profiles, 5-HT2A genotype, and response to treatment with SSRIs in major depression. <i>Journal of Neural Transmission</i> , 2010, 117, 1431-1434.	2.8	5
70	TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. <i>Neuroscience Letters</i> , 2010, 468, 80-84.	2.1	34
71	Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. <i>Neuroscience Letters</i> , 2010, 477, 105-108.	2.1	69
72	Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. <i>Psychiatry Research</i> , 2010, 176, 85-87.	3.3	32

#	ARTICLE	IF	CITATIONS
73	Leisure-time physical activity and metabolic syndrome plus depressive symptoms in the FIN-D2D survey. <i>Preventive Medicine</i> , 2010, 51, 466-470.	3.4	16
74	ACE polymorphism and response to electroconvulsive therapy in major depression. <i>Neuroscience Letters</i> , 2009, 458, 122-125.	2.1	20
75	5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. <i>NeuroReport</i> , 2009, 20, 1125-1128.	1.2	103
76	RGS4 polymorphism and response to electroconvulsive therapy in major depressive disorder. <i>Neuroscience Letters</i> , 2008, 437, 25-28.	2.1	16
77	Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia. <i>Human Psychopharmacology</i> , 2007, 22, 211-215.	1.5	22
78	Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach. <i>BMC Psychiatry</i> , 2007, 7, 22.	2.6	39
79	Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia. <i>Neuroscience Letters</i> , 2006, 407, 195-198.	2.1	32
80	Interaction of tumor necrosis alpha G308A and epidermal growth factor gene polymorphisms in early-onset schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 279-283.	3.2	19
81	Review: over 25% of people with schizophrenia, psychoses, or severe mental disorders fail to adhere to treatment programmes. <i>Evidence-Based Mental Health</i> , 2004, 7, 40-40.	4.5	2
82	Apolipoprotein E polymorphism is associated with age of onset in schizophrenia. <i>Journal of Human Genetics</i> , 2004, 49, 355-359.	2.3	25
83	Patient characteristics and diagnostic discrepancy in first-episode psychosis. <i>Comprehensive Psychiatry</i> , 2004, 45, 213-218.	3.1	22
84	Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 303-307.	5.7	42
85	Association of EGF polymorphism with schizophrenia in Finnish men. <i>NeuroReport</i> , 2004, 15, 1215-1218.	1.2	36
86	Neuregulin genotype and medication response in Finnish patients with schizophrenia. <i>NeuroReport</i> , 2004, 15, 2517-2520.	1.2	44
87	Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. <i>European Neuropsychopharmacology</i> , 2003, 13, 147-151.	0.7	32
88	Dopamine receptor D2 141C Insertion/Deletion polymorphism in a Finnish population with schizophrenia. <i>Psychiatry Research</i> , 2003, 121, 89-92.	3.3	14
89	NOTCH4 gene promoter polymorphism is associated with the age of onset in schizophrenia. <i>Psychiatric Genetics</i> , 2003, 13, 61-63.	1.1	28
90	Catechol-O-methyltransferase and Monoamine Oxidase A Genotypes and Drug Response to Conventional Neuroleptics in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 429-434.	1.4	44

#	ARTICLE	IF	CITATIONS
91	Indicators of medication compliance in first-episode psychosis. <i>Psychiatry Research</i> , 2002, 110, 39-48.	3.3	143
92	The reliability of compliance assessments performed by doctors and patients during neuroleptic treatment: a comparison of compliance ratings. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 299-304.	4.5	3
93	The reliability of compliance assessments performed by doctors and patients during neuroleptic treatment: a comparison of compliance ratings. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 299-304.	4.5	7
94	Enhancing the implementation of evidence-based treatment interventions. A comprehensive evaluation of a real-world implementation programme. <i>Nordic Journal of Psychiatry</i> , 0, , 1-1.	1.3	0
95	Severe mental disorders and COVID-19: a one-year systematic review. <i>Nordic Journal of Psychiatry</i> , 0, , 1-1.	1.3	1